ZTS · Healthcare

Zoetis Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

• Market Demand TrendsImportance 25 · Surprise 32
  Zoetis reported softer demand in its companion-animal market, driven by fewer veterinary clinic visits and greater pet-owner price sensitivity. The weakness affected demand for pet-health products and contributed to…
• Competition and Pricing PressureImportance 20 · Surprise 24
  Zoetis faced heightened competition in the animal-health industry, particularly within its Companion Animal business. Competitive pressure was cited alongside lower clinic traffic and pet-owner price sensitivity as a…
• Competition and Market ShareImportance 20 · Surprise 24
  Zoetis reported heightened competition in the animal health industry, particularly in its Companion Animal business. Softer veterinary clinic traffic and greater pet-owner price sensitivity weakened demand for pet…

10-Q · 2026-08-06

• Liquidity and Debt PositionImportance 70 · Surprise 56
  Cash and cash equivalents declined 40% to $1,476 million at June 30, 2026, from $2,450 million at December 31, 2025, while long-term debt remained nearly flat at $9,048 million versus $9,042 million. Working capital…
• Convertible Senior NotesImportance 64 · Surprise 42
  Zoetis completed a $2.0 billion private offering of 0.250% convertible senior notes on December 18, 2025, with maturity on June 15, 2029 and an initial conversion price of approximately $148.20 per share. Net proceeds…
• Long-term Debt IssuanceImportance 64 · Surprise 42
  On August 18, 2025, Zoetis issued $850 million of 4.150% senior notes due 2028 and $1.00 billion of 5.000% senior notes due 2035. Net proceeds were used to redeem $600 million of 5.400% notes due 2025 and $750 million…
• Competition and Pricing PressureImportance 60 · Surprise 40
  U.S. companion animal revenue declined 11% in both the three- and six-month periods ended June 30, 2026, primarily because of softer end-market demand and an increasingly competitive landscape. The key dermatology…
• Macroeconomic Consumer PressureImportance 60 · Surprise 40
  U.S. companion-animal revenue declined by $240 million, or 11%, in the six months ended June 30, 2026. Zoetis attributed the decline partly to softer end-market demand, heightened competition and macroeconomic-driven…
• Revolving Credit FacilityImportance 58 · Surprise 42
  In August 2025, Zoetis entered into a $1.25 billion senior unsecured revolving credit facility that expires in August 2030. The company may increase the facility to $1.75 billion subject to conditions, and the maximum…
• International Segment GrowthImportance 54 · Surprise 40
  International segment revenue increased 12% to $2,322 million in the six months ended June 30, 2026, with operational revenue up 7% or $141 million. Operational growth included $72 million from companion animal…
• Capital Return ProgramImportance 52 · Surprise 42
  Zoetis’ August 2024 board authorization permits up to $6 billion of common-stock repurchases, with $1.3 billion remaining as of June 30, 2026. During the first six months of 2026, the company repurchased 11.0 million…
• Revenue Performance and MixImportance 49 · Surprise 32
  Six-month revenue increased 1% to $4,730 million from $4,672 million, while operational revenue declined 1% because key-franchise volume fell approximately 3%. Price growth of approximately 1% and volume growth from…
• Geographic Market CommentaryImportance 48 · Surprise 40
  The U.S. market weakened, with segment revenue down 7% in both the quarter and year-to-date period, driven by companion animal products despite livestock growth. International revenue increased 8% in the quarter and…
• FX / Currency ImpactImportance 43 · Surprise 32
  For the six months ended June 30, 2026, approximately 46% of Zoetis’s $4,730 million revenue was denominated in foreign currencies, while approximately 54% was in U.S. dollars. Exposure includes the Australian dollar,…
• Disease Outbreak ImpactImportance 40 · Surprise 42
  Zoetis stated that animal disease outbreaks can reduce demand for livestock products by lowering regional or global sales of animal-derived food products and restricting exports. In the six months ended June 30, 2026,…
• Product Launch and TransitionImportance 38 · Surprise 60
  Zoetis launched Lenivia and Portela in international markets as long-acting monoclonal antibody pain products. The launches contributed to increased demand for small animal diagnostics and monoclonal antibody pain…
• Supply Chain ConstraintsImportance 38 · Surprise 24
  Improved supply availability supported higher U.S. cattle product sales during the quarter and year-to-date period. Cattle demand was additionally elevated in response to the New World screwworm outbreak. Zoetis…
• Headcount / RestructuringImportance 37 · Surprise 42
  Restructuring charges in the three and six months ended June 30, 2026 were primarily driven by employee termination costs under Zoetis’s comprehensive cost and productivity program. The six-month period also included…
• U.S. Segment Revenue DeclineImportance 37 · Surprise 32
  U.S. segment revenue decreased 7% in the three and six months ended June 30, 2026, with companion animal declines of $132 million and $240 million, respectively, partially offset by livestock increases of $42 million…
• Trade Policy and TariffsImportance 37 · Surprise 42
  Starting in early 2025, the United States announced additional tariffs on goods imported from numerous countries, including measures affecting trade relations with China, Canada and the European Union. Multiple nations…
• ERP Transformation and ComplianceImportance 37 · Surprise 42
  Effective January 1, 2026, Zoetis eliminated the one-month reporting lag for International Subsidiaries as part of a multi-year enterprise resource planning (ERP) transition. The company described the broader…
• Operating Expense TrendsImportance 31 · Surprise 32
  Six-month SG&A expense decreased 1%, or $8 million, primarily because of lower depreciation, lower certain significant items and lower charitable contributions. Six-month R&D expense increased 8%, or $25 million, due…
• Operating Cash Flow TrendsImportance 31 · Surprise 32
  Net cash provided by operating activities decreased 6% to $1,056 million in the six months ended June 30, 2026, from $1,120 million in the prior-year period. The decline reflected lower net income adjusted by non-cash…
• Gross Margin DriversImportance 25 · Surprise 32
  Consolidated cost of sales increased to 27.8% of revenue in the six months ended June 30, 2026 from 27.4% in the prior-year period. The higher cost ratio reflected unfavorable product mix and foreign exchange, partly…
• Income Tax Rate ChangesImportance 18 · Surprise 14
  The six-month effective tax rate declined to 20.4% in 2026 from 21.2% in 2025, reducing the tax burden on six-month pretax income. The decline was primarily due to a more favorable jurisdictional mix of earnings and…

8-K · 2026-08-06

• Management ChangesImportance 31 · Surprise 42
  Zoetis appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In the newly created role, Saccaro will lead global finance, including…
• Leadership TransitionImportance 31 · Surprise 42
  Zoetis appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. The newly created role combines leadership of global finance, capital…

8-K · 2026-08-06

• Headcount / RestructuringImportance 77 · Surprise 82
  Zoetis recorded $77 million of restructuring charges and acquisition- and divestiture-related costs in the second quarter, up from $30 million in the prior-year quarter. Other restructuring charges and…
• Guidance / OutlookImportance 73 · Surprise 76
  Zoetis reduced full-year 2026 revenue guidance to $9.120 billion to $9.320 billion from $9.680 billion to $9.960 billion previously. The revised revenue outlook represents organic operational growth of negative 3% to…
• Segment ProfitabilityImportance 48 · Surprise 40
  Second-quarter U.S. earnings declined 10% to $837 million as U.S. revenue fell 7% and gross margin contracted to 83.1% from 84.7%. International earnings increased 12% to $661 million as revenue grew 8%, gross profit…
• Macroeconomic Factors ImpactImportance 48 · Surprise 40
  Management reported a more pressured U.S. Companion Animal market, citing lower clinic visits and pet-owner price sensitivity. U.S. Companion Animal revenue declined 11% in the second quarter, while the key dermatology…
• Revenue Performance and MixImportance 43 · Surprise 32
  Second-quarter revenue was $2.468 billion, flat on a reported basis and down 1% on an organic operational basis from $2.474 billion in the prior-year quarter. Companion Animal revenue declined 5% to $1.708 billion,…
• Market Demand TrendsImportance 42 · Surprise 40
  Zoetis reported a more pressured U.S. Companion Animal market, with lower clinic visits and pet-owner price sensitivity reducing demand. U.S. Companion Animal sales declined 11%, including continued weakness in…
• Geographic Market CommentaryImportance 42 · Surprise 40
  International revenue increased 6% organically in the quarter, while U.S. revenue declined 7%. Quarterly organic growth was strongest in other emerging markets at 21%, Germany at 19%, and Italy, Spain and other…
• Acquisition / Partnership / DivestitureImportance 38 · Surprise 60
  Zoetis completed its acquisition of VitalRADS in July 2026, adding a veterinary teleradiology services platform to its Global Diagnostics business. The platform provides around-the-clock access to board-certified…
• ESG and sustainabilityImportance 34 · Surprise 42
  Zoetis published its 2025 Sustainability Report in June 2026, completing its initial Driven to Care aspirations established in 2021. The company introduced a next phase focused on Communities, Animals and the Planet.…
• Product Launch and TransitionImportance 31 · Surprise 42
  Zoetis launched Lenivia and Portela in Canada and the European Union, with both products providing dogs and cats up to three months of osteoarthritis pain relief from a single injection. Lenivia was also approved in…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  Zoetis received European Commission marketing authorization in July 2026 for Poulvac Procerta HVT-ND, a poultry vaccine targeting Newcastle and Marek’s disease. Dectomax-CA1 received FDA conditional approval for…
• Operating Expense TrendsImportance 30 · Surprise 14
  Second-quarter reported SG&A expense declined 4% to $592 million, while adjusted SG&A declined 3% to $586 million and included $6 million of business-process-transformation costs. Reported R&D expense increased 4% to…
• Competition and Pricing PressureImportance 30 · Surprise 40
  Zoetis said lower clinic visits and pet-owner price sensitivity heightened competitive pressure across parts of its Companion Animal portfolio. In the U.S., the dermatology franchise and Simparica Trio faced persistent…
• Net Income and ProfitabilityImportance 26 · Surprise 14
  Second-quarter reported net income declined 5% to $691 million from $726 million, while reported diluted EPS increased 1% to $1.65 because diluted weighted-average shares declined to 417.7 million from 445.5 million.…
• FX / Currency HeadwindsImportance 25 · Surprise 32
  Zoetis separates foreign exchange effects from operational and organic operational results in its outlook and reported performance. The 2026 guidance is based on foreign exchange rates as of July 21, 2026, with revenue…
• Products and TechnologyImportance 23 · Surprise 24
  Zoetis expanded Vetscan Opticell capabilities so the point-of-care hematology analyzer offers cellular hemoglobin mean, a measurement previously available only in reference laboratories. The enhancement adds diagnostic…

News · 2026-08-06

• Guidance / OutlookImportance 57 · Surprise 60
  Zoetis reduced its full-year 2026 revenue and adjusted-profit outlook after second-quarter revenue missed expectations. The forecast reduction reflects softer pet healthcare demand, lower veterinary traffic, pet-owner…
• Management ChangesImportance 31 · Surprise 42
  Zoetis appointed James (Jay) Saccaro as executive vice president, chief financial officer and chief operating officer effective August 17, 2026. The newly created role combines leadership of global finance with…
• Revenue Performance and MixImportance 25 · Surprise 32
  Zoetis reported second-quarter 2026 revenue of approximately $2.5 billion, flat year over year and down 1% on an organic operational basis. Reported sales of $2.468 billion missed analyst estimates. Companion Animal…
• Market Demand TrendsImportance 25 · Surprise 32
  Zoetis reported softer demand in its companion-animal market, driven by fewer veterinary clinic visits and greater pet-owner price sensitivity. The weakness affected demand for pet-health products and contributed to…
• Competition and Pricing PressureImportance 20 · Surprise 24
  Zoetis faced heightened competition in the animal-health industry, particularly within its Companion Animal business. Competitive pressure was cited alongside lower clinic traffic and pet-owner price sensitivity as a…
• Net Income and ProfitabilityImportance 18 · Surprise 14
  Zoetis reported second-quarter 2026 net income of $691 million, down 5% from the prior-year quarter. Reported diluted earnings per share were $1.65, up 1% year over year. Adjusted earnings per share were $1.87,…